Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.58 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | GALR3 | O60755 | 2/20 | 0.47 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6171309 | 0.86 | GALR3 (0.51) | ALOX5APSMN1; SMN2ALDH1A1MAPTPPARG | |
| SCHEMBL6168555 | 0.84 | GALR3 (0.52) | ALOX5APSMN1; SMN2ALDH1A1MAPTPPARG | |
| SCHEMBL1160251 | 0.84 | ALDH1A1 (0.49) | SLC22A12ALOX5APSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6169166 | 0.84 | PPARG (0.57) | SLC22A12ALOX5APSMN1; SMN2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6172792 | 0.83 | GALR3 (0.51) | ALOX5APSMN1; SMN2ALDH1A1MAPTPPARG | |
| SCHEMBL6170410 | 0.81 | GALR3 (0.48) | ALOX5APSMN1; SMN2ALDH1A1MAPTPPARG | |
| SCHEMBL6170938 | 0.80 | PPARG (0.56) | ALOX5APSMN1; SMN2ALDH1A1MAPTPPARG | |
| SCHEMBL6170933 | 0.79 | ALDH1A1 (0.49) | SLC22A12ALOX5APSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL6170935 | 0.79 | ALDH1A1 (0.49) | SLC22A12ALOX5APSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL1160088 | 0.79 | POLB (0.51) | SMN1; SMN2ALDH1A1MAPTPPARGTNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882718-B1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO (JP) | 2005-08-31 | — | — | EP | disclosed |
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6352985-B1 | CARDIOVASCULAR DISORDERS OR GASTROINTESTINAL DISORDERS, DIABETES (TYPE II DIABETES), DIABETIC COMPLICATIONS METHOD FOR LOWERING THE BLOOD SUGAR LEVEL OF A PATIENT, | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-03-05 | — | — | US | disclosed |
| US-6348032-B1 | POTENT COMPOUNDS THAT INDUCE APOPTOSIS IN NEOPLASTIC CELLS (BUT NOT SUBSTANTIALLY IN NORMAL CELLS), WITHOUT SUBSTANTIALLY INHIBITING PGE-2. | CELL PATHWAYS, INC. | 2002-02-19 | — | — | US | disclosed |
| US-6166219-A | Benzimidazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| EP-0882718-A1 | BENZIMIDAZOLE DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082280-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | SLC22A12 4439/4885ALOX5AP 3905/4885SMN1; SMN2 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.